REG - BkofA Merrill Lynch AbbVie Inc. - Form 38.5 (b) - AbbVie Inc
RNS Number : 4976MBank of America Merrill Lynch11 May 2020FORM 38.5(b)
IRISH TAKEOVER PANEL
DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997,
TAKEOVER RULES, 2013
DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT
RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNIZED INTERMEDIARY
STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY
1.
KEY INFORMATION
Name of exempt principal trader
Bank of America, N.A., Proprietary
Company dealt in
AbbVie Inc
Class of relevant security to which the
dealings being disclosed relate(Note 1)Common - US00287Y1091
Date of dealing
08/05/2020
2.
INTERESTS AND SHORT POSITIONS
(a)
Interests and short positions (following dealing) in the class of relevant security
dealt in (Note 2)
Class of relevant security: Common
US00287Y1091
Long
Short
Number
%
Number
%
(1)
Relevant securities
1,744,657
0.118%
2,618,234
0.177 %
(2)
Derivatives (other than options):
3,532,215
0.239%
2,737,226
0.185%
(3)
Options and agreements to purchase/sell:
0
0%
0
0%
Total
5,276,872
0.357%
5,355,460
0.363%
(b)
Interests and short positions in relevant securities of the company, other than the
class dealt in (Note 2)
Class of relevant security:
Long
Short
Number
%
Number
%
(1)
Relevant securities
0
0%
0
0%
(2)
Derivatives (other than options):
0
0%
0
0%
(3)
Options and agreements to purchase/sell:
0
0%
0
0%
Total
0
0%
0
0%
3.
DEALINGS (Note 3)
(a)
Purchases and sales
Purchase/sale
Number of relevant securities
Price per unit (Note 4)
Purchase
7
82.66 USD
Purchase
1
83.37 USD
Purchase
2
83.42 USD
Purchase
101
83.45 USD
Purchase
2
83.46 USD
Purchase
5
83.47 USD
Purchase
1
83.485 USD
Purchase
5
83.49 USD
Purchase
3
83.5 USD
Purchase
3
83.51 USD
Purchase
2
83.52 USD
Purchase
110
83.53 USD
Purchase
6
83.54 USD
Purchase
208
83.55 USD
Purchase
1
83.56 USD
Purchase
2
83.58 USD
Purchase
4
83.63 USD
Purchase
5
83.64 USD
Purchase
7
83.65 USD
Purchase
102
83.66 USD
Purchase
3
83.665 USD
Purchase
3
83.67 USD
Purchase
2
83.68 USD
Purchase
4
83.69 USD
Purchase
300
83.71 USD
Purchase
2
83.77 USD
Purchase
9
83.785 USD
Purchase
100
83.79 USD
Purchase
102
83.8 USD
Purchase
103
83.81 USD
Purchase
3
83.82 USD
Purchase
105
83.83 USD
Purchase
203
83.84 USD
Purchase
3
83.85 USD
Purchase
204
83.88 USD
Purchase
102
83.89 USD
Purchase
200
83.91 USD
Purchase
100
83.92 USD
Purchase
200
83.94 USD
Purchase
402
83.95 USD
Purchase
64,862
83.96 USD
Purchase
710
83.97 USD
Purchase
423
83.98 USD
Purchase
306
83.99 USD
Purchase
347
84 USD
Purchase
329
84.01 USD
Purchase
9
84.02 USD
Purchase
13
84.03 USD
Purchase
2
84.04 USD
Purchase
8
84.06 USD
Purchase
424
84.07 USD
Purchase
300
84.08 USD
Purchase
204
84.09 USD
Purchase
103
84.1 USD
Purchase
222
84.11 USD
Purchase
2
84.115 USD
Purchase
137
84.12 USD
Purchase
1
84.13 USD
Purchase
1
84.135 USD
Purchase
1
84.14 USD
Purchase
200
84.15 USD
Purchase
277
84.16 USD
Purchase
330
84.17 USD
Purchase
503
84.18 USD
Purchase
177
84.22 USD
Purchase/sale
Number of relevant securities
Price per unit (Note 4)
Sale
2,800
83.439 USD
Sale
9
83.785 USD
Sale
25,623
83.96 USD
Sale
175
84.22 USD
(b)
Derivatives transactions (other than options transactions)
Product name,
e.g. CFDNature of transaction
(Note 5)Number of relevant securities
(Note 6)Price per unit
(Note 4)Swaps
Increasing a Long Position
2,800
83.434 USD
(c)
Options transactions in respect of existing relevant securities
(i)
Writing, selling, purchasing or varying
Product name, e.g. call option
Writing, selling, purchasing, varying etc.
Number of securities to which the option relates (Note 7)
Exercise price
Type, e.g. American, European etc
Expiry date
Option money paid/ received per unit (Note 4)
N/A
N/A
N/A
N/A
N/A
N/A
N/A
(ii)
Exercising
Product name,
e.g. call optionNumber of securities
Exercise price per
unit (Note 4)N/A
N/A
N/A
(d)
Other dealings (including transactions in respect of new securities) (Note 3)
Nature or transaction
(Note 7)Details
Price per unit
(if applicable) (Note 4)N/A
N/A
N/A
4.
OTHER INFORMATION
Agreements, arrangements or understandings relating to options or derivatives
Full details of any agreement, arrangement or understanding between the person
disclosing and any other person relating to the voting rights of any relevant
securities under any option referred to on this form or relating to the voting rights
or future acquisition or disposal of any relevant securities to which any derivative
referred to on this form is referenced. If none, this should be stated.None
Is a Supplemental Form 38.5(b) attached? (Note 8)
No
Date of disclosure
11/05/2020
Contact name
Tolu Tade
Telephone number
+44207 996 3410
Name of offeree/offeror with which connected
AbbVie Inc
Nature of connection (Note 9)
Advisor to - AbbVie Inc
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.ENDISEBFLFFBELLBBD
Recent news on Abbvie
See all newsRCS - Ripple Therapeutics - Ripple Therapeutics Announces Collaboration
AnnouncementREG - Stock Exch Notice - Admission to ISM - 20/06/2024
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
AnnouncementREG - JPMorgan Inv. Trusts - Ten Largest Investments
Announcement